These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study. Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284 [TBL] [Abstract][Full Text] [Related]
28. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. Baril DT; Marone LK; Kim J; Go MR; Chaer RA; Rhee RY J Vasc Surg; 2008 Sep; 48(3):627-33. PubMed ID: 18727966 [TBL] [Abstract][Full Text] [Related]
29. Primary stenting in femoropopliteal occlusive disease - what is the appropriate role? Yiu WK; Conte MS Circ J; 2015; 79(4):704-11. PubMed ID: 25766515 [TBL] [Abstract][Full Text] [Related]
30. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582 [TBL] [Abstract][Full Text] [Related]
31. Eluvia™ peripheral stent system for the treatment of peripheral lesions above the knee. Müller-Hülsbeck S Expert Opin Drug Deliv; 2016; 13(11):1639-1644. PubMed ID: 27580488 [TBL] [Abstract][Full Text] [Related]
32. New stents for SFA. MINAR E; SCHILLINGER M J Cardiovasc Surg (Torino); 2009 Oct; 50(5):635-45. PubMed ID: 19741579 [TBL] [Abstract][Full Text] [Related]
33. Role of stents, drug-eluting stents, and stent-grafts in treatment of infrainguinal arterial disease. Tang GL; Morasch MD Semin Vasc Surg; 2007 Mar; 20(1):37-41. PubMed ID: 17386362 [TBL] [Abstract][Full Text] [Related]
34. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. Ansel GM; Jaff MR; Popma JJ; Battisti AJ; Lottes AE; Harnish P; Dake MD J Endovasc Ther; 2017 Aug; 24(4):499-503. PubMed ID: 28485182 [TBL] [Abstract][Full Text] [Related]
35. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease. Chan YC; Cheng SW; Cheung GC J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015 [TBL] [Abstract][Full Text] [Related]
36. Endovascular interventions in iliac and infrainguinal occlusive artery disease. Ruef J; Hofmann M; Haase J J Interv Cardiol; 2004 Dec; 17(6):427-35. PubMed ID: 15546296 [TBL] [Abstract][Full Text] [Related]
37. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. Katsanos K; Geisler BP; Garner AM; Zayed H; Cleveland T; Pietzsch JB BMJ Open; 2016 May; 6(5):e011245. PubMed ID: 27160845 [TBL] [Abstract][Full Text] [Related]
38. Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials. Acin F; de Haro J; Bleda S; Varela C; Esparza L J Endovasc Ther; 2012 Oct; 19(5):585-95. PubMed ID: 23046322 [TBL] [Abstract][Full Text] [Related]
39. [Evolution of stents for the treatment of femoral artery lesions]. Lejay A; Thaveau F; Bajcz C; Georg Y; Kretz JG; Durand B; Chakfé N J Mal Vasc; 2011 Jun; 36(3):169-73. PubMed ID: 21482057 [TBL] [Abstract][Full Text] [Related]
40. Drug-delivering endovascular treatment versus angioplasty in artery occlusion diseases: a systematic review and meta-analysis. Chen X; Li J; Zheng C; He Y; Jia J; Wang X; Li D; Shang T; Li M Curr Med Res Opin; 2018 Jan; 34(1):95-105. PubMed ID: 28837370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]